Halozyme Therapeutics Inc Strategic Asset Allocation Index
Halozyme Therapeutics Inc strategic asset allocation index. Halozyme Therapeutics Inc (HALO) has a Strategic Asset Allocation Index of 30.0% as of September 2023. Strategic assets (PP&E of $74.67 Million plus long-term investments of $-) total $74.67 Million, measured against net assets of $249.18 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check HALO intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Halozyme Therapeutics Inc (2004–2022)
Strategic asset allocation index of Halozyme Therapeutics Inc from 2004 to 2022. This chart shows how Halozyme Therapeutics Inc's Strategic Asset Allocation Index has evolved across 17 annual periods from 2004 to 2022. As of September 2023, the index stands at 30.0%, representing strategic assets of $74.67 Million against net assets of $249.18 Million USD.
Halozyme Therapeutics Inc Strategic Asset Allocation Index by Year (2004–2022)
Halozyme Therapeutics Inc strategic asset allocation index by year from 2004 to 2022. The table below presents the year-by-year Strategic Asset Allocation Index for Halozyme Therapeutics Inc from 2004 to 2022, covering 17 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Halozyme Therapeutics Inc stock valuation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 44.5% | $75.57 Million | $75.57 Million | $- | $169.80 Million | ▲ +40.0 pp |
| 2021 | 4.5% | $8.79 Million | $8.79 Million | $- | $196.95 Million | ▼ -2.5 pp |
| 2020 | 7.0% | $10.59 Million | $10.59 Million | $- | $151.05 Million | ▼ -4.8 pp |
| 2019 | 11.8% | $10.86 Million | $10.86 Million | $- | $91.77 Million | ▲ +8.8 pp |
| 2018 | 3.0% | $7.46 Million | $7.46 Million | $- | $248.89 Million | ▲ +1.3 pp |
| 2017 | 1.7% | $3.52 Million | $3.52 Million | $- | $208.37 Million | ▼ -7.5 pp |
| 2015 | 9.2% | $3.94 Million | $3.94 Million | $- | $43.00 Million | ▲ +2.0 pp |
| 2014 | 7.1% | $2.95 Million | $2.95 Million | $- | $41.35 Million | ▼ -0.4 pp |
| 2012 | 7.6% | $3.70 Million | $3.70 Million | $- | $48.85 Million | ▼ -8.7 pp |
| 2011 | 16.2% | $1.77 Million | $1.77 Million | $- | $10.90 Million | ▲ +7.2 pp |
| 2010 | 9.1% | $1.85 Million | $1.85 Million | $- | $20.35 Million | ▼ -30.2 pp |
| 2009 | 39.2% | $2.71 Million | $2.71 Million | $- | $6.90 Million | ▲ +22.6 pp |
| 2008 | 16.6% | $2.55 Million | $2.55 Million | $- | $15.38 Million | ▲ +12.6 pp |
| 2007 | 4.0% | $2.28 Million | $2.28 Million | $- | $57.77 Million | ▲ +1.8 pp |
| 2006 | 2.2% | $497.00K | $497.00K | $- | $23.08 Million | ▲ +0.1 pp |
| 2005 | 2.1% | $381.00K | $381.00K | $- | $18.21 Million | ▲ +0.5 pp |
| 2004 | 1.6% | $235.00K | $235.00K | $- | $14.82 Million | — |